ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025 [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that during the Class Period, defendants made false or misleading statements regarding Actinium's data and its likelihood of FDA approval for the Iomab-B Biologics License Application [5] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Specifics - The lawsuit alleges that Actinium's data from the Sierra Trial was unlikely to meet FDA guidelines, which could lead to the rejection of the Iomab-B BLA [5] - The claims include that the additional analyses provided to the FDA were also unlikely to satisfy the necessary guidelines, leading to materially misleading statements about Actinium's business prospects [5]